Primex Clinical Laboratories v. Dept. of Health Services CA3

CourtCalifornia Court of Appeal
DecidedJune 30, 2015
DocketC074343
StatusUnpublished

This text of Primex Clinical Laboratories v. Dept. of Health Services CA3 (Primex Clinical Laboratories v. Dept. of Health Services CA3) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Primex Clinical Laboratories v. Dept. of Health Services CA3, (Cal. Ct. App. 2015).

Opinion

Filed 6/30/15 Primex Clinical Laboratories v. Dept. of Health Services CA3 NOT TO BE PUBLISHED

California Rules of Court, rule 8.1115(a), prohibits courts and parties from citing or relying on opinions not certified for publication or ordered published, except as specified by rule 8.1115(b). This opinion has not been certified for publication or ordered published for purposes of rule 8.1115.

IN THE COURT OF APPEAL OF THE STATE OF CALIFORNIA THIRD APPELLATE DISTRICT (Sacramento) ----

PRIMEX CLINICAL LABORATORIES, INC., C074343

Plaintiff and Appellant, (Super. Ct. No. 34-2012- 80001187-CU-WM-GDS) v.

DEPARTMENT OF HEALTH SERVICES,

Defendant and Respondent.

In 2000, the Department of Health Services (Department) informed Primex Clinical Laboratories, Inc. (Primex), a provider of Medi-Cal services, that Primex was under investigation for various violations of Medi-Cal provisions. In connection with that investigation, the Department withheld Primex’s Medi-Cal payments for services and suspended Primex as a Medi-Cal provider. In 2004, the parties settled the case, allowing the Department to retain the funds withheld from Primex during the investigation and reinstating Primex as a Medi-Cal provider.

1 Nearly eight years after the settlement, Primex filed this action by way of a petition for writ of mandate, asserting that Primex was entitled to the funds ($685,820.44) the Department withheld during the investigation. The trial court denied the petition. We affirm. The settlement allowed the Department to retain the funds, and nothing in the statutory scheme requires now that the Department pay it to Primex. BACKGROUND It appears that there is no dispute concerning the facts (as opposed to their legal effect), so we recount the facts as stated by the trial court. “Primex is a licensed clinical laboratory participating in the Medi-Cal program. “In or about October 2000, the Department received notice that Primex was committing possible violations of various Medi-Cal provisions. On October 17, 18, and 26, 2000, Department staff conducted onsite investigations of Primex’s labs and records. “On or about February 14, 2001, the Department received an email from the federal Health Care Financing Agency (now known as the Centers for Medicare and Medicaid) to stop Medicare payments to Primex because it was being sanctioned by the federal government. The HCFA also informed staff at the Department that some of Primex’s directors were the subject of a federal criminal investigation being undertaken by the Federal Bureau of Investigation. “On March 29, 2001, the Department issued a letter informing Primex that pursuant to Welfare and Institutions Code sections 14107.11 and 14043.6 and 42 C.F.R. § 455.23, the Department was temporarily suspending and deactivating Primex’s Medi-Cal provider number and withholding 100% of the payments owed to Primex as a Medi-Cal provider (the ‘Temporary Suspension and Withhold’). The letter identified possible violations of licensing laws and standards, and advised Primex that it was under investigation for possible fraud, abuse, or willful misrepresentation in the Medi-Cal program. The alleged deficiencies included: failing to supply patient testing documents; failing to give notice of reportable diseases; failing to report patient test results in a

2 timely manner; billing for tests for which no supporting documentation was available; receiving invalid referrals; performing more tests than required; performing and billing for tests that were not medically necessary; allowing unlicensed personnel to perform testing; providing lab testing to clients at less than the cost reimbursed by the Medi-Cal program (overbilling); reporting test results that are incompatible with human life; failing to enroll in proficiency testing; and failing to notify clients of critical test values. “Following the Temporary Suspension and Withhold, on June 26, 2001, the Department issued a Statement of Deficiencies describing Primex’s alleged violations of the licensing laws and standards. The list of deficiencies was substantially the same as that identified in the March 29, 2001, letter. Primex responded with an itemized Plan of Correction, which the Department accepted. “On October 10, 2001, the Department served Primex with a Notice of Intent to Impose Civil Money Penalties for the previously-identified deficiencies. “October 17, 2001, the Department issued a Notice of Sanction[] to Primex, assessing a penalty of $136,000 for licensing violations, plus $13,865 for investigative costs, for a total penalty of $149,865. Primex appealed the Notice of Sanction[]. “During the pendency of Primex’s appeal, the State Controller’s Office initiated and completed an audit of Primex’s billing records. The audit resulted in no adverse findings against Primex. “In July 2004, Primex and the Department settled the appeal arising from the Notice of Sanction[]. The Settlement Agreement refers to the October 2000 investigation of Primex’s labs; the July 3, 2001, Statement of Deficiencies; the October 9, 2001, Notice of Intent to Impose Civil Money Penalties; and the October 17, 2002, Notice of Sanction[]. The Settlement Agreement also refers to the March 29, 2001, Temporary Suspension and Withhold, and indicates that, as of the date of the Settlement Agreement, the Department was withholding $835,685.44 of Primex’s Medi-Cal earnings.

3 “The Settlement Agreement recites that the parties have discussed the issues raised by the ‘Notice of Sanction, and by the imposition of the Temporary Suspension and Withhold,’ and agreed to resolve these issues. Under the Settlement Agreement, Primex agreed to pay, from the funds withheld by the Department, civil money penalties and investigation costs in the amount of $149,865 to the Department’s Lab Field Services Branch. In exchange, the Department agreed to lift the Temporary Suspension and Withhold and reactivate Primex’s Medi-Cal provider number. The parties also agreed that ‘[t]he Department shall retain the remainder of the [withheld funds], totaling $685,820.44.’ “In the general provisions of the Settlement Agreement, the parties agreed that the settlement resolved ‘only the issues dealt with in the above-referenced Notice of Sanction,’ and that nothing in the Agreement ‘restricts the filing of a criminal prosecution nor limits any claims that may be made therein or binds any federal, other state, or local prosecuting, administrative, or regulatory authorities.’ “The parties also agreed to ‘waive all rights either party may have to further litigate, in any forum, as between the parties, the issues raised by this appeal.’ “In August 2004, shortly after the Settlement Agreement, the Department released $149,865 from the Withhold for payment to the State of the civil money penalties and investigation costs, and directed that the balance of the Withhold be transferred to the Health Care Deposit Fund, which is part of the State’s General Fund. The transfer had the effect of liquidating any funds remaining in the temporary withhold account. “From 2004 through June 2012, Primex took no action to recover or inquire about the balance of the withheld funds. On June 22, 2012, Primex filed the present action seeking a peremptory writ of mandate compelling the Department to release and remit to Primex the balance of the withheld funds, totaling $685,820.44, plus interest.” The trial court determined that the “critical issue” was how to interpret the provision of the settlement agreement providing that the Department “shall retain” the

4 remaining funds in the withhold.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Khavarian Enterprises, Inc. v. Commline, Inc.
216 Cal. App. 4th 310 (California Court of Appeal, 2013)
Bodinson Manufacturing Co. v. California Employment Commission
109 P.2d 935 (California Supreme Court, 1941)
Terhune v. Superior Court
76 Cal. Rptr. 2d 841 (California Court of Appeal, 1998)
People v. Harris
10 Cal. App. 4th 672 (California Court of Appeal, 1992)
American Alternative Insurance v. Superior Court
37 Cal. Rptr. 3d 918 (California Court of Appeal, 2006)
Bergeron v. Department of Health Services
83 Cal. Rptr. 2d 481 (California Court of Appeal, 1999)
Founding Members of Newport Beach Country Club v. Newport Beach Country Club, Inc.
135 Cal. Rptr. 2d 505 (California Court of Appeal, 2003)
Rodriguez v. Solis
1 Cal. App. 4th 495 (California Court of Appeal, 1991)
Morey v. Vannucci
64 Cal. App. 4th 904 (California Court of Appeal, 1998)
Wright v. Coberly-West Co.
250 Cal. App. 2d 31 (California Court of Appeal, 1967)

Cite This Page — Counsel Stack

Bluebook (online)
Primex Clinical Laboratories v. Dept. of Health Services CA3, Counsel Stack Legal Research, https://law.counselstack.com/opinion/primex-clinical-laboratories-v-dept-of-health-services-ca3-calctapp-2015.